Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prednisone + cytarabine + vincristine + mercaptopurine
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intrathecal, Subcutaneous
01
Overview
Prednisone + cytarabine + vincristine + mercaptopurine is a multi-agent chemotherapy regimen primarily utilized in the treatment of hematologic malignancies, such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This combination employs four distinct mechanisms to target malignant cell populations: prednisone, a synthetic corticosteroid, induces apoptosis in lymphoid cells via glucocorticoid receptor activation; cytarabine (Ara-C), a pyrimidine nucleoside analog, inhibits DNA polymerase and DNA synthesis during the S-phase of the cell cycle; vincristine, a vinca alkaloid, binds to tubulin to prevent microtubule polymerization, leading to mitotic arrest; and mercaptopurine (6-MP), a purine analog, acts as an antimetabolite that interferes with de novo purine synthesis and nucleic acid production. The regimen is typically administered in cycles as part of induction, consolidation, or maintenance protocols to achieve and maintain remission.
- Other names
- Ara-C + 6-MP + VCR + PrednisoneCytarabine + Mercaptopurine + Vincristine + Prednisone
02
Targets
PPAT (Amidophosphoribosyltransferase)DNA polymerase familyGR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on prednisone + cytarabine + vincristine + mercaptopurine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prednisone + cytarabine + vincristine + mercaptopurine.